Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

This study improves the diagnosis and treatment of histiocytosis — a rare group of diseases caused by abnormal growth of immune cells — in patients under 18 years old by analyzing genetic mutations in tumor tissue and blood. Researchers will also evaluate whether a PET-CT scan using a radioactive sugar (fluorodeoxyglucose) can accurately detect disease activity in these patients. Children under 18 with a confirmed or suspected histiocytosis diagnosis are eligible, provided they or their guardians can provide informed consent. Participation involves genetic testing from tissue or blood samples and imaging with PET-CT scans as part of the diagnostic process. This summary was prepared to help patients understand the study in plain language.